DK1443942T3 - Farmaceutisk sammensætning til anvendelse ved behandling af maligniteter omfattende en kombination af et bisphosphonat, en COX-2 inhibitor og en taxol - Google Patents

Farmaceutisk sammensætning til anvendelse ved behandling af maligniteter omfattende en kombination af et bisphosphonat, en COX-2 inhibitor og en taxol

Info

Publication number
DK1443942T3
DK1443942T3 DK02801899T DK02801899T DK1443942T3 DK 1443942 T3 DK1443942 T3 DK 1443942T3 DK 02801899 T DK02801899 T DK 02801899T DK 02801899 T DK02801899 T DK 02801899T DK 1443942 T3 DK1443942 T3 DK 1443942T3
Authority
DK
Denmark
Prior art keywords
taxol
cox
inhibitor
malignancies
treatment
Prior art date
Application number
DK02801899T
Other languages
English (en)
Inventor
Jonathan Green
Allan Lipton
Lois Mary Witters
Original Assignee
Novartis Ag
Allan Lipton
Lois Mary Witters
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Allan Lipton, Lois Mary Witters filed Critical Novartis Ag
Application granted granted Critical
Publication of DK1443942T3 publication Critical patent/DK1443942T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK02801899T 2001-10-19 2002-10-18 Farmaceutisk sammensætning til anvendelse ved behandling af maligniteter omfattende en kombination af et bisphosphonat, en COX-2 inhibitor og en taxol DK1443942T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34592101P 2001-10-19 2001-10-19
PCT/EP2002/011696 WO2003035081A1 (en) 2001-10-19 2002-10-18 Pharmaceutical composition for use for the treatment of malignancies comprising in combination a bisphosphonates, a cox-2 inhibitor and a taxol

Publications (1)

Publication Number Publication Date
DK1443942T3 true DK1443942T3 (da) 2008-05-19

Family

ID=23357099

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02801899T DK1443942T3 (da) 2001-10-19 2002-10-18 Farmaceutisk sammensætning til anvendelse ved behandling af maligniteter omfattende en kombination af et bisphosphonat, en COX-2 inhibitor og en taxol

Country Status (26)

Country Link
US (1) US7345088B2 (da)
EP (1) EP1443942B1 (da)
JP (1) JP2005506371A (da)
KR (1) KR20040066103A (da)
CN (1) CN100372539C (da)
AT (1) ATE382347T1 (da)
AU (1) AU2002363089B2 (da)
BR (1) BR0213410A (da)
CA (1) CA2461085A1 (da)
CO (1) CO5570672A2 (da)
DE (1) DE60224429T2 (da)
DK (1) DK1443942T3 (da)
EC (1) ECSP045054A (da)
ES (1) ES2301710T3 (da)
HK (1) HK1080733A1 (da)
HU (1) HUP0402061A3 (da)
IL (2) IL161090A0 (da)
MX (1) MXPA04003671A (da)
NO (1) NO20042056L (da)
NZ (1) NZ532282A (da)
PL (1) PL367707A1 (da)
PT (1) PT1443942E (da)
RU (1) RU2317819C2 (da)
SI (1) SI1443942T1 (da)
WO (1) WO2003035081A1 (da)
ZA (1) ZA200402089B (da)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0204756D0 (en) * 2002-02-28 2002-04-17 Novartis Ag Organic compounds
GB0328040D0 (en) * 2003-12-03 2004-01-07 Coleman Robert E Pharmaceutical uses of bisphosphonates
FR2939314A1 (fr) * 2008-12-04 2010-06-11 Univ Victor Segalen Bordeaux 2 Nouvelles compositions et methodes pour la potentialisation des signaux d'apoptose dans les cellules tumorales
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
CN102573809B (zh) * 2009-07-31 2017-07-21 格兰泰股份有限公司 结晶方法和生物利用度
US20160016982A1 (en) 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
WO2012071517A2 (en) 2010-11-24 2012-05-31 Thar Pharmaceuticals, Inc. Novel crystalline forms
US10195218B2 (en) 2016-05-31 2019-02-05 Grunenthal Gmbh Crystallization method and bioavailability

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1187130A (zh) * 1995-06-06 1998-07-08 麦克公司 用二磷酸盐预防与免疫抑制疗法有关的骨损失
KR20010110310A (ko) * 1998-12-23 2001-12-12 로저 에이. 윌리암스 종양 치료에 사이클로옥시게나제-2 억제제와 하나 이상의항종양제를 조합치료법으로서 사용하는 방법
AU3653301A (en) * 2000-01-28 2001-08-07 Merck & Co., Inc. Treatment or prevention of prostate cancer with a cox-2 selective inhibiting drug

Also Published As

Publication number Publication date
IL161090A (en) 2010-04-15
ZA200402089B (en) 2005-06-22
US20050014726A1 (en) 2005-01-20
KR20040066103A (ko) 2004-07-23
RU2004115337A (ru) 2005-04-20
US7345088B2 (en) 2008-03-18
BR0213410A (pt) 2004-11-03
HK1080733A1 (en) 2006-05-04
SI1443942T1 (sl) 2008-08-31
ECSP045054A (es) 2004-05-28
MXPA04003671A (es) 2005-06-20
CN100372539C (zh) 2008-03-05
DE60224429D1 (de) 2008-02-14
CO5570672A2 (es) 2005-10-31
PT1443942E (pt) 2008-04-07
IL161090A0 (en) 2004-08-31
HUP0402061A2 (hu) 2005-02-28
WO2003035081A1 (en) 2003-05-01
RU2317819C2 (ru) 2008-02-27
CN1703226A (zh) 2005-11-30
PL367707A1 (en) 2005-03-07
NO20042056L (no) 2004-05-18
JP2005506371A (ja) 2005-03-03
ATE382347T1 (de) 2008-01-15
AU2002363089B2 (en) 2006-02-16
EP1443942A1 (en) 2004-08-11
NZ532282A (en) 2006-02-24
EP1443942B1 (en) 2008-01-02
HUP0402061A3 (en) 2007-05-29
CA2461085A1 (en) 2003-05-01
ES2301710T3 (es) 2008-07-01
DE60224429T2 (de) 2008-12-18

Similar Documents

Publication Publication Date Title
DE60129242D1 (de) Verwendung von zoledronsäure zur schmerzbehandlung
HK1080733A1 (en) Pharmaceutical composition for use for the treatment of malignancies comprising in combination a bisphosphonates, a cox-2 inhibitor and a taxol
NO20034549L (no) Behandling av type 2 diabetes med inhibitorer av dipeptidyl peptidase IV
DK1272188T3 (da) Anvendelse af EGFR-tyrosinkinaseinhibitorer til behandling af brystcancer
DK1373215T3 (da) Gelanamycinderivater egnet til behandling af cancer
NO20060398L (no) Anvendelse av en kombinasjon av en epidermal vekstfaktor reseptor kinase inhibitor og cytotoksiske midler for behandling og hemming av kreft
DK0514452T4 (da) Anvendelse af insulin-sensibiliserende midler til behandling af hypertension
DK1365769T3 (da) Lægemiddel til behandling af osteonekrose og til behandling af patienter med risiko for at udvikle osteonekrose
ATE520691T1 (de) Shp-2-hemmer, pharmazeutische zusammensetzung damit und ihre verwendung zur behandlung phosphatase-vermittelter erkrankungen
BR0314081A (pt) Terapia de combinação compreendendo um bisfosfonato e um inibidor de hmg-coa redutase
BRPI0408491A (pt) tratamento da doença de alzheimer
DE60309887D1 (de) Kombination von einem aromatasehemmer mit einem bisphosphonat
GB0020504D0 (en) Therapeutic method
SE0004827D0 (sv) Therapeutic compounds
DE69924385D1 (de) Verwendung von angiotensin zur behandlung von krebsmetastasierung
DE60226126D1 (de) Verwendung von gamma-gt inhibitoren zur behandlung von chronischen degenerativerkrankungen
MXPA05013975A (es) Tratamiento de enfermedades asociadas con amiloide y epileptogenesis.
BR0315376A (pt) Combinações de benzotiadiazóis e inibidores de cox-2 para o tratamento de dor
EA200600987A1 (ru) Применение сирамезина в лечении злокачественных опухолей
NO20051879L (no) Anvendelse av proteintyrosinfosfataseinhibitorer til forhindring og/eller behandling av kreft
UA36041A (uk) Спосіб лікування хронічного панкреатиту, ускладненого псевдокістою
TW200519078A (en) 2-alkylidene-19-nor-vitamin d derivatives for the treatment of a second hip fracture